A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing

Experimental Cell Research

Volumn 312, Issue 15, 2006, Pages 2726-2734

  Ke, Ning ^a   Zhou, Demin ^a   E Chatterton, Jon ^a   Liu, Guohong ^a   Chionis, John ^a   Zhang, Jing ^a   Tsugawa, Lindsey ^a   Lynn, Rebecca ^c   Yu, Dehua ^a   Meyhack, Bernd ^b   Wong Staal, Flossie ^a   Li, Qi Xiang ^a  

^a Immusol Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE

Author keywords

Cancer target; Inducible RNAi; mTOR; PC3; Tet on; Xenograft tumor model

Indexed keywords

DOXYCYCLINE; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; GENE INDUCTION; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; TUMOR REGRESSION; VALIDATION PROCESS; XENOGRAFT;

EID: 33747356189     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.05.001     Document Type: Article

References (34)

1. Sausville E., and Hollingshead M. Mouse models in cancer drug discovery and development. In: Figg W.D., and McLeod H.L. (Eds). Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (2004), Humana Press
2. Kamb A. What's wrong with our cancer models?. Nat. Rev., Drug Discov. 4 (2005) 161-165
3. Wang S., and El-Deiry W.S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64 (2004) 6666-6672
4. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., and Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 (2005) 7249-7258
5. Lin X., Yang J., Chen J., Gunasekera A., Fesik S.W., and Shen Y. Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett. 577 (2004) 376-380
6. Chen Y., Stamatoyannopoulos G., and Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 63 (2003) 4801-4804
7. Czauderna F., Santel A., Hinz M., Fechtner M., Durieux B., Fisch G., Leenders F., Arnold W., Giese K., Klippel A., and Kaufmann J. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 31 (2003) e127
8. Gupta S., Schoer R.A., Egan J.E., Hannon G.J., and Mittal V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1927-1932
9. Matsukura S., Jones P.A., and Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 31 (2003) e77
10. Wiznerowicz M., and Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77 (2003) 8957-8961
11. Hosono T., Mizuguchi H., Katayama K., Xu Z.L., Sakurai F., Ishii-Watabe A., Kawabata K., Yamaguchi T., Nakagawa S., Mayumi T., and Hayakawa T. Adenovirus vector-mediated doxycycline-inducible RNA interference. Hum. Gene Ther. 15 (2004) 813-819
12. van de Wetering M., Oving I., Muncan V., Pon Fong M.T., Brantjes H., van Leenen D., Holstege F.C., Brummelkamp T.R., Agami R., and Clevers H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4 (2003) 609-615
13. Matthess Y., Kappel S., Spankuch B., Zimmer B., Kaufmann M., and Strebhardt K. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene 24 (2005) 2973-2980
14. Ke N., Claassen G., Yu D.H., Albers A., Fan W., Tan P., Grifman M., Hu X., Defife K., Nguy V., Meyhack B., Brachat A., Wong-Staal F., and Li Q.X. Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res. 64 (2004) 8208-8212
15. Waninger S., Kuhen K., Hu X., Chatterton J.E., Wong-Staal F., and Tang H. Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J. Virol. 78 (2004) 12829-12837
16. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev., Cancer 4 (2004) 335-348
17. Dutcher J.P. Mammalian target of rapamycin inhibition. Clin. Cancer Res. 10 (2004) 6382S-6387S
18. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16 (2004) 564-575
19. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
20. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
21. Kim D.H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., Tempst P., and Sabatini D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11 (2003) 895-904
22. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
23. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., and Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10 (2002) 457-468
24. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., and Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10314-10319
25. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62 (2002) 6141-6145
26. Ke N., Albers A., Claassen G., Yu D.H., Chatterton J.E., Hu X., Meyhack B., Wong-Staal F., and Li Q.X. One-week 96-well soft agar growth assay for cancer target validation. BioTechniques 36 (2004) 826-828 (830, 832-3)
27. Ohkawa J., and Taira K. Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. Hum. Gene Ther. 11 (2000) 577-585
28. Tiscornia G., Singer O., Ikawa M., and Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1844-1848
29. Claassen G., Ke N., Yu D.H., Chatterton J.E., Hu X., Albers A., Nguy V., Chionis J., Truong T., Meyhack B., Wong-Staal F., and Li Q.X. Comprehensive assessment of cell growth properties affected by various agents using an integrated and non-subjective approach. Preclinica 2 (2004) 435-439
30. Law M., Forrester E., Chytil A., Corsino P., Green G., Davis B., Rowe T., and Law B. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. 66 (2006) 1070-1080
31. Kielosto M., Nummela P., Katainen R., Leaner V., Birrer M.J., and Holtta E. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun. Cancer Res. 64 (2004) 3772-3779
32. Zawel L., Yu J., Torrance C.J., Markowitz S., Kinzler K.W., Vogelstein B., and Zhou S. DEC1 is a downstream target of TGF-beta with sequence-specific transcriptional repressor activities. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2848-2853
33. Saikali Z., and Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anti-cancer Drugs 14 (2003) 773-778
34. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., and Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24 (2004) 9508-9516